Breaking News

MilliporeSigma Completes $780M Acquisition of Exelead

Adds newly formed CDMO business unit and plans to invest more than €500 million in technology scale-up.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

MilliporeSigma, the U.S. and Canada Life Science business sector of Merck KGaA, Darmstadt, Germany, closed the transaction to acquire Exelead for approximately $780 million in cash. The business combination is expected to enable the Life Science business to provide comprehensive contract development and manufacturing organization (CDMO) services across the mRNA value chain. The Life Science business plans to further invest over €500 million to scale up Exelead’s technology over the next te...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters